Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam(The Alfred Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Kate Burbury(The University of Melbourne), Mathias Bressel(Peter MacCallum Cancer Centre), Sasanka M. Handunnetti(Peter MacCallum Cancer Centre), Martin Dreyling(LMU Klinikum), Mark A. Dawson(The University of Melbourne), Rodney J. Hicks(Flinders Medical Centre), John F. Seymour(The Royal Melbourne Hospital), Mary Ann Anderson(The Royal Melbourne Hospital), Sarah‐Jane Dawson(The University of Melbourne), Rishu Agarwal(Peter MacCallum Cancer Centre), David Westerman(University of Melbourne), Gillian Turner(Peter MacCallum Cancer Centre), Juliana Di Iulio(Peter MacCallum Cancer Centre), Christiane Pott(University Hospital Schleswig-Holstein), Stephen Lade(The University of Texas MD Anderson Cancer Center)
Cited by 429
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k